Aprotinin
drugOn this page
Also known as Aprotinin (bovine)Aprotinin (synthetic)Aprotinin biosyntheticAprotinin bovineAprotinin concentrated solutionAprotininaAprotinineBAYER A 128BAYER-A-128BAYERA-128Bovine aprotininFibrinolysis inhibitorRIKER 52GRIKER-52GRP 9921RP-9921Trasylol
Summary
Aprotinin (CHEMBL1201619) is an approved unknown (ATC B02AB01) targeting PLG; indicated across 3 conditions including pancreatitis and breast neoplasm.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- ATC class: B02AB01
- Targets: 1 (PLG)
- Indications: 3 conditions
- Clinical trials: 7
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201619 |
| Name | Aprotinin |
| Type | Unknown |
| Max phase | 4 |
| ATC | B02AB01 |
Also known as: Aprotinin, Aprotinin (bovine), Aprotinin (synthetic), Aprotinin biosynthetic, Aprotinin bovine, Aprotinin concentrated solution, Aprotinina, Aprotinine, BAYER A 128, BAYER-A-128, BAYERA-128, Bovine aprotinin
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| PLG | plasminogen | Binding | 6.8 | 4.6% | P00747 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): PLG.
Top Reactome pathways
6 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Platelet degranulation | 1 | PLG |
| Degradation of the extracellular matrix | 1 | PLG |
| Activation of Matrix Metalloproteinases | 1 | PLG |
| Signaling by PDGF | 1 | PLG |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 1 | PLG |
| Dissolution of Fibrin Clot | 1 | PLG |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| proteolysis | 1 |
| blood coagulation | 1 |
| negative regulation of cell population proliferation | 1 |
| negative regulation of cell-substrate adhesion | 1 |
| protein processing | 1 |
| extracellular matrix disassembly | 1 |
| tissue regeneration | 1 |
| fibrinolysis | 1 |
| positive regulation of blood vessel endothelial cell migration | 1 |
| myoblast differentiation | 1 |
| muscle cell cellular homeostasis | 1 |
| tissue remodeling | 1 |
| biological process involved in interaction with symbiont | 1 |
| negative regulation of fibrinolysis | 1 |
| positive regulation of fibrinolysis | 1 |
Indications & clinical
Indications
3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| pancreatitis | 1 | MONDO:0004982 | EFO:0000278 |
| breast neoplasm | 1 | MONDO:0021100 | MONDO:0007254 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 7.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE1 | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07317050 | PHASE3 | NOT_YET_RECRUITING | Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment |
| NCT00354900 | PHASE1 | TERMINATED | Phase I Study of Aprotinin in Advanced Breast Cancer |
| NCT00357851 | PHASE1 | COMPLETED | Can Aprotinin Reduce Pancreatitis After Scoliosis Surgery |
| NCT00131040 | Not specified | COMPLETED | Investigation of Leukocyte Trafficking Into Skin Blisters During Cardiopulmonary Bypass |
| NCT00257751 | Not specified | COMPLETED | Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving Antiplatelet Therapy With Clopidogrel (Plavix) |
| NCT00617955 | Not specified | COMPLETED | Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates |
| NCT04527133 | Not specified | UNKNOWN | An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19 |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
11 molecules share ≥1 primary target. Top 11 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| AMINOCAPROIC ACID | ChEMBL | Phase 4 (approved) | PLG |
| BEROTRALSTAT | ChEMBL | Phase 4 (approved) | PLG |
| MELAGATRAN | ChEMBL | Phase 4 (approved) | PLG |
| PENTAMIDINE | ChEMBL | Phase 4 (approved) | PLG |
| TELAPREVIR | ChEMBL | Phase 4 (approved) | PLG |
| TRANEXAMIC ACID | ChEMBL | Phase 4 (approved) | PLG |
| DABIGATRAN | ChEMBL | Phase 3 | PLG |
| GABEXATE | ChEMBL | Phase 3 | PLG |
| MILVEXIAN | ChEMBL | Phase 3 | PLG |
| NAFAMOSTAT | ChEMBL | Phase 3 | PLG |
| EFEGATRAN | ChEMBL | Phase 2 | PLG |
Related Atlas pages
- Genes: PLG
- Drugs: Aminocaproic Acid, Berotralstat, Melagatran, Pentamidine, Telaprevir, Tranexamic Acid, Dabigatran, Gabexate, Milvexian, Nafamostat